

IBL HEALTHCARE LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE
INCOME (Un-audited)
FOR THE PERIOD ENDED MARCH 31, 2022

	Note	Quarter ended		Nine-months ended	
		March 31, 2022	March 31, 2021	March 31, 2022	March 31, 2021
------(Rs. in '000)-----					
Revenue from contracts with customers	12	900,093	805,005	2,673,458	2,241,362
Cost of Sales		(624,935)	(500,004)	(1,787,607)	(1,496,890)
Gross Profit		<u>275,158</u>	<u>305,001</u>	<u>885,851</u>	<u>744,472</u>
Other (loss) / income	13	3,382	4,408	(6,325)	27,145
Marketing and distribution expenses		(140,132)	(138,916)	(423,962)	(360,445)
Administrative and general expenses		(23,800)	(20,988)	(70,155)	(65,282)
Finance cost	14	(5,133)	(8,800)	(16,811)	(23,779)
Profit before taxation		<u>109,475</u>	<u>140,705</u>	<u>368,598</u>	<u>322,112</u>
Income tax expense		(30,025)	(29,860)	(114,852)	(86,238)
Profit after taxation		<u>79,450</u>	<u>110,846</u>	<u>253,746</u>	<u>235,874</u>
Other comprehensive income		-	-	-	-
Total comprehensive income		<u><u>79,450</u></u>	<u><u>110,846</u></u>	<u><u>253,746</u></u>	<u><u>235,874</u></u>
			(Re-stated)		(Re-stated)
Earnings per share - basic and diluted		<u>1.22</u>	<u>1.71</u>	<u>3.91</u>	<u>3.63</u>

The annexed notes 1 to 16 form an integral part of this condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer